Ass Hospitaliere Protestante De Lyon
- Address
- 3 Chemin Du Penthod, 69300 Caluire-et-Cuire, France
Digestive System Diseases
At Ass Hospitaliere Protestante De Lyon, the Rheumatology department conducts research on locally advanced anal squamous cell carcinoma, comparing intensified induction chemotherapy followed by chemoradiotherapy with standard chemoradiotherapy to improve two‑year event‑free survival.
- Induction chemotherapy strategies
- Chemoradiotherapy optimization
- Survival outcomes in anal carcinoma
The study aims to refine treatment protocols and could lead to more effective management options for patients with this rare cancer, with the trial being run at the Lyon facility.
Musculoskeletal Diseases
In the area of musculoskeletal diseases, the Rheumatology unit evaluates novel biologic therapies for psoriatic arthritis, testing subcutaneous sonelokimab against placebo and an active reference arm to achieve high ACR50 response rates.
- Biologic therapy evaluation
- ACR50 response measurement
- Anti‑TNFα inadequate response management
The goal is to provide new options for patients who have not responded adequately to existing treatments, enhancing joint health and quality of life at this French research site.
Skin and Connective Tissue Diseases
The department’s work also encompasses skin and connective tissue diseases, linking the inflammatory processes of psoriatic arthritis with its skin manifestations; the sonelokimab trial assesses both joint and skin improvement, integrating dermatologic outcomes into rheumatologic research.
- Joint and skin efficacy endpoints
- Subcutaneous biologic delivery
- Safety profiling in psoriatic disease
By addressing both arthritis and skin lesions, the research seeks comprehensive relief for patients, positioning the Lyon site as a hub for integrated rheumatology studies.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 1 by active trials.
- 1MoonLake Immunotherapeutics AG1active
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1MoonLake Immunotherapeutics AG2trials
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 978 other sites in France
Therapeutic Area Benchmark — France
Select a therapeutic area to compare against other sites in France.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: France
Market Share
Country: France
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Ass Hospitaliere Protestante De Lyon
lock Showing 1 of 5 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Baricitinib Versus TNF Inhibitors for Venous Thromboembolism Risk in Rheumatoid Arthritis: Phase 3b/4 Active-Controlled Study | Eli Lilly & Co. | Phase III | Not Recruiting | Jul 2019 | Apr 2025 |
IMP list
lock Showing 1 of 14 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Sonelokimab | 2 | Unknown | 2025-03-25 | 2025-03-25 |
Request feasibility information
Ask this centre about capacity, equipment and patient population.
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.